149 related articles for article (PubMed ID: 31780771)
1. The effect of 5 alpha-reductase inhibitor therapy on prostate cancer detection in the era of multi-parametric magnetic resonance imaging.
Kim JK; Lee HJ; Hwang SI; Choe G; Kim HJ; Hong SK
Sci Rep; 2019 Nov; 9(1):17862. PubMed ID: 31780771
[TBL] [Abstract][Full Text] [Related]
2. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
3. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
Hosseiny M; Shakeri S; Felker ER; Lu D; Sayre J; Ahuja P; Raman SS
AJR Am J Roentgenol; 2020 Sep; 215(3):660-666. PubMed ID: 32755166
[No Abstract] [Full Text] [Related]
4. Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; Gandaglia G; Fossati N; Brembilla G; Cristel G; Dehò F; Scattoni V; Maga T; Losa A; Gaboardi F; Cardone G; Esposito A; De Cobelli F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 Jun; 1(2):120-128. PubMed ID: 31100235
[TBL] [Abstract][Full Text] [Related]
5. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.
Wegelin O; Exterkate L; van der Leest M; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; Barentsz JO; Somford DM; van Melick HHE
Eur Urol; 2019 Apr; 75(4):582-590. PubMed ID: 30522912
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM
Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Woo S; Suh CH; Eastham JA; Zelefsky MJ; Morris MJ; Abida W; Scher HI; Sidlow R; Becker AS; Wibmer AG; Hricak H; Vargas HA
Eur Urol Oncol; 2019 Nov; 2(6):605-616. PubMed ID: 31204311
[TBL] [Abstract][Full Text] [Related]
8. Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection.
Morote J; Picola N; Muñoz-Rodriguez J; Paesano N; Ruiz-Plazas X; Muñoz-Rivero MV; Celma A; Manuel GG; Miró B; Servian P; Abascal JM
Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397430
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of MRI targeted prostate biopsy for detecting clinically significant prostate cancer in men with low prostate-specific antigen levels.
Bang S; Yu J; Chung JH; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Lee HM; Jeon SS
Sci Rep; 2021 Nov; 11(1):21951. PubMed ID: 34753938
[TBL] [Abstract][Full Text] [Related]
10. [Real-time MRI/US fusion-guided biopsy in biopsy-naïve and pre-biopsied patients with suspicion for prostate cancer].
Maxeiner A; Stephan C; Fischer T; Durmus T; Kilic E; Asbach P; Haas M; Günzel K; Neymeyer J; Miller K; Cash H
Aktuelle Urol; 2015 Jan; 46(1):34-8. PubMed ID: 25519051
[TBL] [Abstract][Full Text] [Related]
11. [Multiparametric MRI and MRI-TRUS fusion biopsy in patients with prior negative prostate biopsy].
Kesch C; Radtke JP; Distler F; Boxler S; Klein T; Hüttenbrink C; Hees K; Roth W; Roethke M; Schlemmer HP; Hohenfellner M; Hadaschik BA
Urologe A; 2016 Aug; 55(8):1071-7. PubMed ID: 27168038
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of 3T Multiparametric MR Imaging followed by 3T in-Bore MR-Guided Biopsy for Detection of Clinically Significant Prostate Cancer Based on PIRADSv2.1 Score.
Hosseiny M; Felker ER; Azadikhah A; Suvannarerg V; Sayre J; Ponzini D; Ahuja P; Lu D; Raman SS
J Vasc Interv Radiol; 2020 Oct; 31(10):1619-1626. PubMed ID: 32921565
[TBL] [Abstract][Full Text] [Related]
13. Comparing Prostate Imaging-Reporting and Data System Version 2 (PI-RADSv2) Category 1 and 2 Groups: Clinical Implication of Negative Multiparametric Magnetic Resonance Imaging.
Kim JK; Lee HJ; Hwang SI; Choe G; Hong SK
Biomed Res Int; 2020; 2020():2819701. PubMed ID: 32337234
[TBL] [Abstract][Full Text] [Related]
14. Elastic Versus Rigid Image Registration in Magnetic Resonance Imaging-transrectal Ultrasound Fusion Prostate Biopsy: A Systematic Review and Meta-analysis.
Venderink W; de Rooij M; Sedelaar JPM; Huisman HJ; Fütterer JJ
Eur Urol Focus; 2018 Mar; 4(2):219-227. PubMed ID: 28753777
[TBL] [Abstract][Full Text] [Related]
15. MRI-TRUS fusion guided prostate biopsy - initial experience and assessment of the role of contralateral lobe systematic biopsy.
Andras I; Crisan D; Cata E; Tamas-Szora A; Caraiani C; Coman RT; Bungardean C; Mirescu C; Coman I; Crisan N
Med Ultrason; 2019 Feb; 21(1):37-44. PubMed ID: 30779829
[TBL] [Abstract][Full Text] [Related]
16. [Real-time MRI/US fusion-guided biopsy improves detection rates of prostate cancer in pre-biopsied patients].
Maxeiner A; Fischer T; Stephan C; Cash H; Slowinski T; Kilic E; Durmus T
Aktuelle Urol; 2014 May; 45(3):197-203. PubMed ID: 24902069
[TBL] [Abstract][Full Text] [Related]
17. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
[TBL] [Abstract][Full Text] [Related]
18. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.
Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G
Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296
[TBL] [Abstract][Full Text] [Related]
19. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
Moldovan PC; Van den Broeck T; Sylvester R; Marconi L; Bellmunt J; van den Bergh RCN; Bolla M; Briers E; Cumberbatch MG; Fossati N; Gross T; Henry AM; Joniau S; van der Kwast TH; Matveev VB; van der Poel HG; De Santis M; Schoots IG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TB; Rouvière O
Eur Urol; 2017 Aug; 72(2):250-266. PubMed ID: 28336078
[TBL] [Abstract][Full Text] [Related]
20. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
